{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T16:54:52Z","timestamp":1725468892387},"publisher-location":"Chichester, UK","reference-count":38,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003457","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T17:14:00Z","timestamp":1069434840000},"source":"Crossref","is-referenced-by-count":5,"title":["Amino acids for amyotrophic lateral sclerosis \/ motor neuron disease"],"prefix":"10.1002","author":[{"given":"Matthew J","family":"Parton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mitsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P Nigel","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,20]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD003457-BIB1|cit1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00862977","article-title":"A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis","volume":"239","author":"Blin","year":"1992","journal-title":"Journal of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD003457-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1212\/WNL.43.12.2466","article-title":"Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure?","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"8593","key":"10.1002\/14651858.CD003457-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(88)91841-7","article-title":"Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis","volume":"1","author":"Plaitakis","year":"1988","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003457-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.47.5.1220","article-title":"A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data","volume":"47","author":"Tandan","year":"1996","journal-title":"Neurology"},{"issue":"30","key":"10.1002\/14651858.CD003457-BIB5|cit5","first-page":"1469","article-title":"[Short-term double-blind versus placebo trial of L-threonine in amyotrophic lateral sclerosis]","volume":"18","author":"Blin","year":"1989","journal-title":"Presse Medicale"},{"issue":"5","key":"10.1002\/14651858.CD003457-BIB6|cit6","first-page":"392","article-title":"[Anomaly in the neurotransmitter amino acids in amyotrophic lateral sclerosis: a therapeutic application]","volume":"147","author":"Blin","year":"1991","journal-title":"Revue Neurologique (Paris)"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB7|cit7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(00)00489-5","article-title":"Electrophysiologic endpoint measures in a multicenter ALS drug trial","volume":"184","author":"Bromberg","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"issue":"42","key":"10.1002\/14651858.CD003457-BIB8|cit8","first-page":"1472","article-title":"A double-blind placebo-controlled study of branched chain amino acids and L-threonine for the short-term treatment of signs and symptoms of amyotrophic lateral sclerosis. [French]","volume":"68","author":"Gil","year":"1992","journal-title":"La Semaine des H\u00f4pitaux (Paris)"},{"issue":"Suppl (3)","key":"10.1002\/14651858.CD003457-BIB9|cit9","first-page":"454","article-title":"Glycine and L-threonine therapeutic trials in amyotrophic lateral sclerosis (ALS)","volume":"42","author":"Hugon","year":"1992","journal-title":"Neurology"},{"issue":"Suppl (3)","key":"10.1002\/14651858.CD003457-BIB10|cit10","first-page":"454","article-title":"Treatment of amyotrophic lateral sclerosis with branched chain amino acids (BCAA): results of a second study","volume":"42","author":"Plaitakis","year":"1992","journal-title":"Neurology"},{"issue":"166","key":"10.1002\/14651858.CD003457-BIB11|cit11","first-page":"S166","article-title":"Multinational trial of branched-chain amino acids in amyotrophic lateral sclerosis","volume":"Suppl (1)","author":"Steiner","year":"1994","journal-title":"Muscle & Nerve"},{"issue":"8","key":"10.1002\/14651858.CD003457-BIB12|cit12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00328503","article-title":"Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis","volume":"236","author":"Testa","year":"1989","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB13|cit13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0303-8467(92)90110-O","article-title":"Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study","volume":"94","author":"Testa","year":"1992","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"3","key":"10.1002\/14651858.CD003457-BIB14|cit14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ana.410220308","article-title":"A rating scale for amyotrophic lateral sclerosis: description and preliminary experience","volume":"22","author":"Appel","year":"1987","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB15|cit15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp.57.1.119-a","article-title":"Changes in CSF amino acid concentrations during the evolution of amyotrophic lateral sclerosis","volume":"57","author":"Blin","year":"1994","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD003457-BIB16|cit16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.410390519","article-title":"Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex","volume":"39","author":"Bristol","year":"1996","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB17|cit17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0404.1993.tb04186.x","article-title":"Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis [see comments]","volume":"88","author":"Camu","year":"1993","journal-title":"Acta Neurologica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD003457-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp.55.12.1106","article-title":"Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950","volume":"55","author":"Chancellor","year":"1992","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"Pt 3","key":"10.1002\/14651858.CD003457-BIB19|cit19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/118.3.707","article-title":"Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction","volume":"118","author":"Haverkamp","year":"1995","journal-title":"Brain"},{"issue":"9013","key":"10.1002\/14651858.CD003457-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003457-BIB21|cit21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0896-6273(00)80997-6","article-title":"Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis","volume":"20","author":"Lin","year":"1998","journal-title":"Neuron"},{"issue":"8","key":"10.1002\/14651858.CD003457-BIB22|cit22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1212\/WNL.24.8.721","article-title":"The administration of guanidine in amyotrophic lateral sclerosis","volume":"24","author":"Norris","year":"1974","journal-title":"Neurology"},{"issue":"24","key":"10.1002\/14651858.CD003457-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003457-BIB24|cit24","first-page":"354","article-title":"L-Threonine and the modification of ALS","volume":"38","author":"Patten","year":"1988","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD003457-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1212\/WNL.37.12.1845","article-title":"Brain glutamate deficiency in amyotrophic lateral sclerosis","volume":"37","author":"Perry","year":"1987","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB26|cit26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.410280105","article-title":"Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid [comment]","volume":"28","author":"Perry","year":"1990","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003457-BIB27|cit27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.410070403","article-title":"Glutamate dehydrogenase deficiency in three patients with spinocerebellar syndrome","volume":"7","author":"Plaitakis","year":"1980","journal-title":"Annals of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003457-BIB28|cit28","first-page":"78","article-title":"The treatment of GDH-deficient olivopontocerebellar atrophy with branched chain amino acids","volume":"33","author":"Plaitakis","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003457-BIB29|cit29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ana.410150206","article-title":"Neurological disorders associated with deficiency of glutamate dehydrogenase","volume":"15","author":"Plaitakis","year":"1984","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD003457-BIB30|cit30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ana.410220503","article-title":"Abnormal glutamate metabolism in amyotrophic lateral sclerosis","volume":"22","author":"Plaitakis","year":"1987","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003457-BIB31|cit31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.410240314","article-title":"The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis","volume":"24","author":"Plaitakis","year":"1988","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB32|cit32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410280106","article-title":"Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis [comment]","volume":"28","author":"Rothstein","year":"1990","journal-title":"Annals of Neurology"},{"issue":"22","key":"10.1002\/14651858.CD003457-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199205283262204","article-title":"Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis [comment]","volume":"326","author":"Rothstein","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD003457-BIB34|cit34","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1073\/pnas.90.14.6591","article-title":"Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity","volume":"90","author":"Rothstein","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB35|cit35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410380114","article-title":"Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis","volume":"38","author":"Rothstein","year":"1995","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003457-BIB36|cit36","article-title":"Corticosteroids for treating myasthenia gravis (protocol for a Cochrane review)","author":"Schneider","year":"2003","journal-title":"The Cochrane Library"},{"issue":"Suppl","key":"10.1002\/14651858.CD003457-BIB37|cit37","first-page":"96","article-title":"El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis","volume":"124","year":"1994","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD003457-BIB38|cit38","first-page":"1","article-title":"Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House 'Therapeutic Trials in ALS' Workshop Contributors","volume":"129 Suppl","year":"1995","journal-title":"Journal of the Neurological Sciences"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003457\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:20:57Z","timestamp":1628529657000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003457"}},"subtitle":[],"editor":[{"given":"Matthew J","family":"Parton","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2003,10,20]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003457","relation":{},"subject":[],"published":{"date-parts":[[2003,10,20]]}}}